SG11201805364TA - Ointment - Google Patents
OintmentInfo
- Publication number
- SG11201805364TA SG11201805364TA SG11201805364TA SG11201805364TA SG11201805364TA SG 11201805364T A SG11201805364T A SG 11201805364TA SG 11201805364T A SG11201805364T A SG 11201805364TA SG 11201805364T A SG11201805364T A SG 11201805364TA SG 11201805364T A SG11201805364T A SG 11201805364TA
- Authority
- SG
- Singapore
- Prior art keywords
- osaka
- chuo
- shi
- otedori
- international
- Prior art date
Links
- 239000002674 ointment Substances 0.000 title abstract 5
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 241001590997 Moolgarda engeli Species 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- -1 oxazole compound Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 6 July 2017 (06.07.2017) WIPOIPCT (10) International Publication Number WO 2017/115780 A1 (51) International Patent Classification: C07D 263/32 (2006.01) A61P17/00 (2006.01) A61K 31/421 (2006.01) (21) International Application Number: PCT/JP2016/088843 (22) International Filing Date: 27 December 2016 (27.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2015-256784 28 December 2015 (28.12.2015) JP (71) Applicant: OTSUKA PHARMACEUTICAL CO., LTD. [JP/JP]; 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo, 1018535 (JP). (72) Inventors: MURAKAMI, Yoshihiro; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo- ku, Osaka-shi, Osaka, 5400021 (JP). MATSUSHITA, Hitoshi; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). MATSUMOTO, Kengo; c/o OTSUKA PHARMA CEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka- shi, Osaka, 5400021 (JP). OKADA, Minoru; c/o OT SUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). YUKI, Yohei; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). KOY- AMA, Noriyuki; c/o OTSUKA PHARMACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP). KANAI, Naohiko; c/o OTSUKA PHAR MACEUTICAL CO., LTD., 3-2-27, Osaka-shi, Osaka, 5400021 (JP). Otedori, Chuo-ku, (74) Agent: SAEGUSA & PARTNERS; Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: OINTMENT O 00 l> (ll) i-H (57) : An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity O against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin. N
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015256784 | 2015-12-28 | ||
| PCT/JP2016/088843 WO2017115780A1 (en) | 2015-12-28 | 2016-12-27 | Ointment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805364TA true SG11201805364TA (en) | 2018-07-30 |
Family
ID=57851287
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805364TA SG11201805364TA (en) | 2015-12-28 | 2016-12-27 | Ointment |
| SG10201912634QA SG10201912634QA (en) | 2015-12-28 | 2016-12-27 | Ointment |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912634QA SG10201912634QA (en) | 2015-12-28 | 2016-12-27 | Ointment |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10588893B2 (en) |
| EP (1) | EP3397619B1 (en) |
| JP (3) | JP6873128B2 (en) |
| KR (2) | KR20240034867A (en) |
| CN (1) | CN108473448A (en) |
| AU (1) | AU2016382036B2 (en) |
| CA (1) | CA3009734A1 (en) |
| DK (1) | DK3397619T3 (en) |
| ES (1) | ES2811849T3 (en) |
| HK (1) | HK1255187A1 (en) |
| MY (1) | MY197975A (en) |
| PH (1) | PH12018501346A1 (en) |
| SA (1) | SA518391908B1 (en) |
| SG (2) | SG11201805364TA (en) |
| TW (1) | TWI726027B (en) |
| WO (1) | WO2017115780A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202009564TA (en) * | 2018-04-04 | 2020-10-29 | Otsuka Pharma Co Ltd | Oxazole compound crystal |
| JP7051968B2 (en) * | 2019-10-09 | 2022-04-11 | 大塚製薬株式会社 | Oxazole compound crystals |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6419963B1 (en) * | 2001-04-22 | 2002-07-16 | Sarfaraz K Niazi | Composition and method for the treatment of diaper rash using natural products |
| US7655717B2 (en) * | 2002-07-17 | 2010-02-02 | Mary J. Goulbourne | Ointment composition for treating decubitus ulcers and methods for its making and its use |
| WO2004073680A1 (en) * | 2003-02-21 | 2004-09-02 | Shionogi & Co., Ltd. | Ointment of droplet-dispersion type |
| SI1954684T1 (en) * | 2005-11-15 | 2014-07-31 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound and pharmaceutical composition |
| EP2345414B1 (en) * | 2008-10-08 | 2014-06-25 | Takata Seiyaku Co., Ltd. | Tacrolimus preparation for external applications |
| GB0907413D0 (en) * | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| JP5965187B2 (en) * | 2012-03-30 | 2016-08-03 | 小林製薬株式会社 | Oily ointment |
| CN109912526A (en) * | 2012-08-30 | 2019-06-21 | 大塚制药株式会社 | The method for manufacturing oxazoline compound |
-
2016
- 2016-12-26 TW TW105143190A patent/TWI726027B/en active
- 2016-12-27 EP EP16828990.8A patent/EP3397619B1/en active Active
- 2016-12-27 SG SG11201805364TA patent/SG11201805364TA/en unknown
- 2016-12-27 JP JP2018525638A patent/JP6873128B2/en active Active
- 2016-12-27 KR KR1020247006977A patent/KR20240034867A/en not_active Application Discontinuation
- 2016-12-27 SG SG10201912634QA patent/SG10201912634QA/en unknown
- 2016-12-27 US US16/064,618 patent/US10588893B2/en active Active
- 2016-12-27 MY MYPI2018001102A patent/MY197975A/en unknown
- 2016-12-27 CA CA3009734A patent/CA3009734A1/en active Pending
- 2016-12-27 CN CN201680076557.0A patent/CN108473448A/en active Pending
- 2016-12-27 WO PCT/JP2016/088843 patent/WO2017115780A1/en active Application Filing
- 2016-12-27 ES ES16828990T patent/ES2811849T3/en active Active
- 2016-12-27 AU AU2016382036A patent/AU2016382036B2/en active Active
- 2016-12-27 DK DK16828990.8T patent/DK3397619T3/en active
- 2016-12-27 KR KR1020187020807A patent/KR102643824B1/en active IP Right Grant
-
2018
- 2018-06-22 PH PH12018501346A patent/PH12018501346A1/en unknown
- 2018-06-27 SA SA518391908A patent/SA518391908B1/en unknown
- 2018-11-08 HK HK18114305.1A patent/HK1255187A1/en unknown
-
2020
- 2020-02-05 US US16/782,259 patent/US20200171006A1/en not_active Abandoned
-
2021
- 2021-04-19 JP JP2021070099A patent/JP2021107437A/en active Pending
-
2022
- 2022-01-03 US US17/567,582 patent/US20220117944A1/en active Pending
-
2023
- 2023-02-07 JP JP2023016555A patent/JP2023058571A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021107437A (en) | 2021-07-29 |
| JP6873128B2 (en) | 2021-05-19 |
| NZ743851A (en) | 2021-09-24 |
| CN108473448A (en) | 2018-08-31 |
| AU2016382036A1 (en) | 2018-07-12 |
| TW201729806A (en) | 2017-09-01 |
| CA3009734A1 (en) | 2017-07-06 |
| EP3397619B1 (en) | 2020-07-29 |
| PH12018501346B1 (en) | 2019-02-18 |
| PH12018501346A1 (en) | 2019-02-18 |
| HK1255187A1 (en) | 2019-08-09 |
| TWI726027B (en) | 2021-05-01 |
| KR102643824B1 (en) | 2024-03-07 |
| US20200171006A1 (en) | 2020-06-04 |
| WO2017115780A1 (en) | 2017-07-06 |
| JP2023058571A (en) | 2023-04-25 |
| MY197975A (en) | 2023-07-25 |
| ES2811849T3 (en) | 2021-03-15 |
| KR20240034867A (en) | 2024-03-14 |
| US20220117944A1 (en) | 2022-04-21 |
| DK3397619T3 (en) | 2020-08-24 |
| AU2016382036B2 (en) | 2021-02-04 |
| EP3397619A1 (en) | 2018-11-07 |
| KR20180097672A (en) | 2018-08-31 |
| US20190000810A1 (en) | 2019-01-03 |
| SG10201912634QA (en) | 2020-02-27 |
| SA518391908B1 (en) | 2022-06-05 |
| JP2019503989A (en) | 2019-02-14 |
| US10588893B2 (en) | 2020-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201806429PA (en) | Substituted piperidine compound and use thereof | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors |